Suppr超能文献

AM 251能持续减少食物摄入量和体重,且不会产生耐受性和条件性味觉厌恶。

AM 251 produces sustained reductions in food intake and body weight that are resistant to tolerance and conditioned taste aversion.

作者信息

Chambers Adam P, Koopmans Henry S, Pittman Quentin J, Sharkey Keith A

机构信息

Department of Physiology & Biophysics, Hotchkiss Brain Institute and Institute of Infection, Inflammation and Immunity, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.

出版信息

Br J Pharmacol. 2006 Jan;147(1):109-16. doi: 10.1038/sj.bjp.0706439.

Abstract

The cannabinoid 1 (CB(1)) receptor has been implicated in the regulation of food intake. Here, we examine the effect of the CB(1) receptor antagonist AM 251 on food intake and body weight over a prolonged period. Further, we examine whether AM 251 produces conditioned taste aversion (CTA) and if sustained antagonism at central receptors contributes to its anorectic effect. The effect of AM 251 of food intake and body weight was examined in daily (1 mg kg(-1)) and 5-day (5 mg kg(-1)) dosing schedules. Matching reductions in food intake and body weight were observed in both paradigms. A single administration of AM 251 (5 mg kg(-1)) significantly reduced food intake for 4 days. Tolerance to the anorectic effects of AM 251 did not develop in either dosing strategy. Active avoidance of AM 251 (3; 5 mg kg(-1), i.p.) was examined using a CTA assay. Rats showed no evidence of CTA associated with AM 251. We investigated the sustained effect of AM 251 (5 mg kg(-1), i.p.) on CB(1) receptors in the hypothalamus using Delta(9)-tetrahydrocannabinol (8 mg kg(-1), i.p.) induced hypothermia. AM 251 initially blocked hypothermia, but this effect was not seen 2 or 4 days later. The results demonstrate that smaller, or infrequent, administrations of AM 251 can produce sustained reductions in food intake and body weight in rat. Reductions in food intake were sustained longer than AM 251 antagonized the effects of a CB(1) receptor agonist in the hypothalamus, and occurred independently of CTA.

摘要

大麻素1(CB(1))受体与食物摄入的调节有关。在此,我们研究了CB(1)受体拮抗剂AM 251在较长时期内对食物摄入和体重的影响。此外,我们还研究了AM 251是否会产生条件性味觉厌恶(CTA),以及中枢受体的持续拮抗作用是否有助于其厌食作用。在每日(1 mg kg(-1))和5日(5 mg kg(-1))给药方案中研究了AM 251对食物摄入和体重的影响。在两种给药方案中均观察到食物摄入量和体重的相应降低。单次给予AM 251(5 mg kg(-1))可使食物摄入量在4天内显著减少。两种给药策略均未产生对AM 251厌食作用的耐受性。使用CTA试验检测了对AM 251(3;5 mg kg(-1),腹腔注射)的主动回避情况。大鼠未表现出与AM 251相关的CTA迹象。我们使用δ9 - 四氢大麻酚(8 mg kg(-1),腹腔注射)诱导的体温过低现象,研究了AM 251(5 mg kg(-1),腹腔注射)对下丘脑CB(1)受体的持续作用。AM 251最初可阻断体温过低现象,但在2天或4天后未观察到这种作用。结果表明,较小剂量或不频繁给予AM 251可使大鼠的食物摄入量和体重持续降低。食物摄入量的降低持续时间长于AM 251在下丘脑拮抗CB(1)受体激动剂的作用时间,且与CTA无关。

相似文献

2
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat.
Physiol Behav. 2004 Oct 15;82(5):863-9. doi: 10.1016/j.physbeh.2004.07.004.
3
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.
Psychopharmacology (Berl). 2005 Jul;180(2):286-93. doi: 10.1007/s00213-005-2171-0. Epub 2005 Mar 15.
7
Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake.
Neuropharmacology. 2004 Sep;47(4):593-603. doi: 10.1016/j.neuropharm.2004.06.002.

引用本文的文献

2
Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice.
Saudi Pharm J. 2023 Feb;31(2):255-264. doi: 10.1016/j.jsps.2022.12.011. Epub 2022 Dec 29.
4
Cannabinoids affect the mouse visual acuity via the cannabinoid receptor type 2.
Sci Rep. 2020 Sep 25;10(1):15819. doi: 10.1038/s41598-020-72553-y.
5
Inhibition of fatty acid amide hydrolase in the CNS prevents and reverses morphine tolerance in male and female mice.
Br J Pharmacol. 2020 Jul;177(13):3024-3035. doi: 10.1111/bph.15031. Epub 2020 Mar 30.
6
The novel cannabinoid CB receptor agonist AM11101 increases food intake in female rats.
Br J Pharmacol. 2019 Oct;176(20):3972-3982. doi: 10.1111/bph.14797. Epub 2019 Sep 6.
7
Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.
Br J Pharmacol. 2019 May;176(10):1524-1540. doi: 10.1111/bph.14453. Epub 2018 Aug 22.
9
Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.
Eur J Pharmacol. 2014 Jan 5;722:134-46. doi: 10.1016/j.ejphar.2013.09.068. Epub 2013 Nov 1.
10
Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.
Neuropharmacology. 2013 Jul;70:268-77. doi: 10.1016/j.neuropharm.2013.02.009. Epub 2013 Feb 24.

本文引用的文献

1
Review article: endocannabinoids and their receptors in the enteric nervous system.
Aliment Pharmacol Ther. 2005 Oct 15;22(8):667-83. doi: 10.1111/j.1365-2036.2005.02648.x.
3
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.
Psychopharmacology (Berl). 2005 Jul;180(2):286-93. doi: 10.1007/s00213-005-2171-0. Epub 2005 Mar 15.
4
Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.
J Biol Chem. 2005 Jul 1;280(26):25196-201. doi: 10.1074/jbc.C500175200. Epub 2005 May 16.
6
Endocannabinoid control of food intake and energy balance.
Nat Neurosci. 2005 May;8(5):585-9. doi: 10.1038/nn1457.
10
Endocannabinoid receptor antagonists: potential for obesity treatment.
Treat Endocrinol. 2004;3(6):345-60. doi: 10.2165/00024677-200403060-00003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验